Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial.

"

 Financial disclosures: Ge Yu certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. Financial disclosures:"

"

Financial disclosures: Ge Yu certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. 

Funding/Support and role of the sponsor: The article processing charge was funded by the PHOTO project, which was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (11/142/02). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The funding body had no direct role in the study."

"The PHOTO trial (ISRCTN registry no. ISRCTN84013636) was a multicentre, pragmatic, open-label, parallel-group, randomised controlled trial that compared PDD-TURBT and WL-TURBT for participants with a first diagnosis of NMIBC suspected to be at intermediate or high risk of recurrence according to visual characteristics. In total, 538 participants were recruited from November 2014 to February 2018 and followed up to September 2020 in 22 UK NHS hospitals. Eligible individuals were aged ≥16 yr with a suspected first diagnosis of intermediate- or high-risk NMIBC according to the European Organisation for Research and Treatment of Cancer (EORTC)/European Association of Urology and National Institute for Health and Care Excellence (NICE) risk tables. Exclusion criteria were: (1) low-risk NMIBC; (2) imaging evidence of MIBC; (3) upper-tract involvement; (4) another life-threatening malignancy in the previous 2 yr; (5) evidence of metastases; (6) porphyria or known porphyrin hypersensitivity; (7) pregnancy; and (8) any other contraindications to PDD or WL surgery."